New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution
Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific accumulation in the tumor, favorable...
Brain
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
-Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy...
Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects
The US Government Granted Athena GTX a $2,866,000 Final Development Contract Award!JACKSON CENTER, Pa., March 17, 2025 (GLOBE NEWSWIRE) --...
ProDentim Under Review: Why Taking Probiotics for Stronger Teeth & Healthier Gums is Trending
How Probiotics Are Transforming Dental Health and Redefining Oral HygieneTALLMADGE, Ohio, March 15, 2025 (GLOBE NEWSWIRE) -- In 2025, the...
NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit
SANTA ANA, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage...
The ADDF’s Diagnostics Accelerator Authors New Paper on Ocular Biomarker Landscape, Highlighting Ocular Tests as a Tool for Early Detection of Alzheimer’s Disease
New findings published in Alzheimer's & Dementia suggest blood biomarkers are expected to become the standard method for diagnosing Alzheimer's,...
World-first ISO Requirements for child-friendly services for victims of violence launched today during the 58th Human Rights Council
GENEVA, March 12, 2025 /PRNewswire/ -- In a historic move to combat the global crisis of violence against children, ISO has...
Life Time Brings Trusted, Proven Line of LTH-Branded Supplements to Amazon
Rigorously tested, research-backed LTH protein powders, electrolytes, fish oil and more now available CHANHASSEN, Minn., March 12, 2025 /PRNewswire/ -- Life...
Next-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical Testing
Harnessing generative AI to develop targeted therapies for DNA damage response, including hard-to-treat central nervous system malignanciesVANCOUVER, British Columbia, March...
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model
Alzheimer’s disease (AD), affecting around 6.9 million people in the US, is ranked as the seventh leading cause of death...
Prime Biome Reviews And Complaints: A Detailed Study Released That’s Needs to Be Adopted for Which Type of Peoples?
ST. PETERSBURG, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- This is a comprehensive examination of the groundbreaking research behind Prime...
Lindus Health and Sooma Medical announce pivotal device clinical trial for treatment of MDD
BOSTON, March 11, 2025 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science...
NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
Submission for New Intended Use That Leverages Company’s Patented OneRF® Technology Platform Expected in May 2025 EDEN PRAIRIE, Minn., March...
Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
LONDON, March 11, 2025 (GLOBE NEWSWIRE) -- Kaerus Bioscience (www.kaerusbio.com), a clinical-stage biopharmaceutical company created by Medicxi for the development...
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease
Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer...
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by FDA for CRB-701...
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as...
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure...
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM...
BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year...